{
  "id": "5c61bacae842deac67000001",
  "type": "yesno",
  "question": "Is cariprazine effective for treatment of bipolar disorder?",
  "ideal_answer": "Yes, cariprazine is effective for bipolar disorder.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28843918",
    "http://www.ncbi.nlm.nih.gov/pubmed/24048386",
    "http://www.ncbi.nlm.nih.gov/pubmed/23361832",
    "http://www.ncbi.nlm.nih.gov/pubmed/27190727",
    "http://www.ncbi.nlm.nih.gov/pubmed/26586950",
    "http://www.ncbi.nlm.nih.gov/pubmed/30323605",
    "http://www.ncbi.nlm.nih.gov/pubmed/27396597",
    "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
    "http://www.ncbi.nlm.nih.gov/pubmed/28478771",
    "http://www.ncbi.nlm.nih.gov/pubmed/27059102",
    "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
    "http://www.ncbi.nlm.nih.gov/pubmed/28343051",
    "http://www.ncbi.nlm.nih.gov/pubmed/25562205",
    "http://www.ncbi.nlm.nih.gov/pubmed/23966785",
    "http://www.ncbi.nlm.nih.gov/pubmed/25056368",
    "http://www.ncbi.nlm.nih.gov/pubmed/30470662",
    "http://www.ncbi.nlm.nih.gov/pubmed/26510944",
    "http://www.ncbi.nlm.nih.gov/pubmed/29119668",
    "http://www.ncbi.nlm.nih.gov/pubmed/26655189",
    "http://www.ncbi.nlm.nih.gov/pubmed/30372510",
    "http://www.ncbi.nlm.nih.gov/pubmed/25532076"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: We evaluated the safety/tolerability of longer-term open-label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cariprazine is FDA approved for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DISCUSSION: Cariprazine-treated patients with bipolar I disorder attained clinically significant improvement in manic symptoms as shown by significantly greater rates of response and remission versus placebo; improvement in manic symptoms did not induce depressive symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28478771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30372510",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}